程序性死亡配体 1 表达在非小细胞肺癌中的作用及其与临床病理因素和诊断标志物的相关性和预后意义。
Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers.
机构信息
Department of Thoracic Surgery, Wroclaw Medical University, Wroclaw 53-439, Poland.
Department of Thoracic Surgery, Lower Silesian Centre of Lung Diseases, Wroclaw 53-439, Poland.
出版信息
Int J Mol Sci. 2019 Feb 14;20(4):824. doi: 10.3390/ijms20040824.
BACKGROUND
The latest immunotherapy, used in the treatment of non-small cell lung cancer (NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) to inhibit its interaction with the PD-1 receptor. Elevated levels of PD-L1 expression were observed on NSCLC cells. The association between PD-L1 expression and clinicopathological features is still unclear. Therefore, we examined this relationship and also compare PD-L1 expression levels with Ki-67, p63 and TTF-1.
METHODS
866 samples of NSCLCs were used to prepare tissue microarrays (TMAs) on which immunohistochemical (IHC) reactions were performed. Changes in the level of () gene expression in 62 NSCLC tumors were tested in relation to 14 normal lung tissues by real-time PCR reactions (RT-PCR).
RESULTS
PD-L1 expression was observed in 32.6% of NSCLCs. PD-L1 expression was increased in higher malignancy grades (G) ( < 0.0001) and in higher lymph node status (pN) ( = 0.0428). The patients with low PD-L1 expression had longer overall survival compared to the group with high expression ( = 0.0332) in adenocarcinoma (AC) only.
CONCLUSIONS
PD-L1 expression seems to be associated with increased tumor proliferation and aggressiveness as well as shorter patient survival in NSCLC, predominantly in the AC group.
背景
最新的免疫疗法用于治疗非小细胞肺癌（NSCLC），使用针对程序性死亡配体 1（PD-L1）的单克隆抗体来抑制其与 PD-1 受体的相互作用。在 NSCLC 细胞上观察到 PD-L1 表达水平升高。PD-L1 表达与临床病理特征之间的关联尚不清楚。因此，我们检查了这种关系，并将 PD-L1 表达水平与 Ki-67、p63 和 TTF-1 进行了比较。
方法
使用 866 个 NSCLCs 样本制备组织微阵列（TMA），并对其进行免疫组织化学（IHC）反应。通过实时 PCR 反应（RT-PCR）测试 62 个 NSCLC 肿瘤中 () 基因表达水平的变化与 14 个正常肺组织的关系。
结果
在 32.6%的 NSCLCs 中观察到 PD-L1 表达。PD-L1 表达在恶性程度较高的分级（G）中增加（<0.0001），在淋巴结状态较高的 pN 中增加（=0.0428）。仅在腺癌（AC）中，低 PD-L1 表达的患者总生存期比高表达组长（=0.0332）。
结论
PD-L1 表达似乎与 NSCLC 中肿瘤增殖和侵袭性增加以及患者生存时间缩短有关，主要在 AC 组中。
Zotero 插件